Keyphrases
Bullous Pemphigoid
100%
Controlled Experiment
12%
Clinical Trials
12%
Disease Severity
12%
High Dose
12%
Autoantibodies
12%
Comorbidity
12%
Treatment Options
12%
Potential Treatments
12%
Severe Cases
12%
Adverse Effects
12%
Immune Signaling
12%
B Lymphocytes
12%
Interleukin-4 (IL-4)
12%
Anti-CD20 Antibody
12%
Interleukin-17 (IL-17)
12%
Interleukin-13 (IL-13)
12%
Pruritus
12%
Novel Therapies
12%
Drug Exposure
12%
Th2 Response
12%
Improved Outcomes
12%
Rituximab
12%
Eosinophils
12%
Immunoglobulin E Antibodies
12%
Omalizumab
12%
Cumulative Dose
12%
Topical Therapy
12%
Dupilumab
12%
Junction Formation
12%
Dosing Regimen
12%
Complement Inhibitors
12%
Safety Self-efficacy
12%
Systemic Corticosteroids
12%
Systemic Glucocorticoids
12%
Interleukin-4 Receptor
12%
BP180
12%
Autoimmune Bullous Disease
12%
BP230
12%
Optimal Dosing
12%
Dermal-epidermal Junction
12%
Blister Formation
12%
Chronic Use
12%
IL-23 Inhibitors
12%
Bullous Lesions
12%
Tildrakizumab
12%
Secukinumab
12%
Novel Treatments
12%
Rising Incidence
12%
Janus Kinase Inhibitors
12%
Increasing Life Expectancy
12%
Corticosteroid Tapering
12%
Efgartigimod
12%
Neonatal Fc Receptor Antagonist
12%
Nomacopan
12%
Pharmacology, Toxicology and Pharmaceutical Science
Bullous Pemphigoid
100%
Diseases
25%
Clinical Trial
12%
Controlled Clinical Trial
12%
Glucocorticoid
12%
Disease Severity
12%
Immunoglobulin E Antibody
12%
Pruritus
12%
Interleukin 4
12%
Fc Receptor
12%
Dupilumab
12%
Rituximab
12%
Life Expectancy
12%
Interleukin 23
12%
Complement Inhibitor
12%
Nomacopan
12%
Blister
12%
Interleukin 4 Receptor
12%
Vesicular Rash
12%
Bertilimumab
12%
Tildrakizumab
12%
Monoclonal Antibody
12%
Receptor Antagonist
12%
Omalizumab
12%
Autoantibodies
12%
Interleukin 13
12%
Interleukin 17
12%
Janus Kinase Inhibitor
12%
Secukinumab
12%
Clobetasol Propionate
12%
Comorbidity
12%
Corticosteroid
12%
Immunology and Microbiology
Bullous Pemphigoid
100%
Autoantibodies
12%
B Cell
12%
Nomacopan
12%
Neonatal Fc Receptor
12%
Interleukin-4 Receptor
12%
Dermoepidermal Junction
12%
Tildrakizumab
12%
Bertilimumab
12%
Immunity
12%
Immunoglobulin E Antibody
12%
Monoclonal Antibody
12%
Interleukin 23
12%
Drug Megadose
12%
CD20
12%
Interleukin 13
12%
Drug Exposure
12%
Omalizumab
12%
Rituximab
12%
Dupilumab
12%
Life Expectancy
12%
Complement Inhibitor
12%
Secukinumab
12%
Interleukin 4
12%
Eosinophil
12%
Comorbidity
12%
Interleukin 17
12%
Glucocorticoid
12%